[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Mons\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":71},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100642157","evaluation-of-calcified-coronary-lesion-preparation-with-the-naviscore-scoring-balloon-100642157",false,"NCT07650578","Evaluation of Calcified Coronary Lesion Preparation With the Naviscore Scoring Balloon","MILOU: Minimize Intra Luminal Obstructive Underexpansion: A Prospective, Multi-Center Randomized Trial for the Evaluation of Calcified Coronary Lesion Preparation With the Naviscore Scoring Balloon","MILOU","Inclusion Criteria:\n\n* Patient written consent is given, ≥18 years.\n* A de novo lesion to be treated in a vessel between 2.5 and 4.0 mm.\n* Moderate to heavily calcified lesions detected by coronary angiography on two orthogonal views, and confirmed by IVUS if the lesion can be crossed with the catheter.\n\nExclusion Criteria:\n\n* Patient \\\u003C18 years old.\n* Pregnant female.\n* Contraindication to dual antiplatelet therapy.\n* Thrombocytopenia (under 100 000).\n* Major surgical intervention planned within one year.\n* Significant left main lesion.\n* Chronic total occlusion.\n* Lesion in a graft.\n* In-stent restenosis lesion.\n* Lesion responsible of a ST elevated Myocardial Infarction (STEMI)","ALL","18 Years",{"count":20,"type":21},200,"ESTIMATED","INTERVENTIONAL",[24],"NA","The purpose of this clinical study is to evaluate the effectiveness and safety of a specialized medical device, the Naviscore scoring balloon, in preparing calcified coronary artery narrowings before the implantation of a drug-eluting stent. During percutaneous coronary interventions, the presence of calcified plaques in the heart arteries represents a major challenge because it can prevent stents from expanding fully. When a stent remains under-expanded, it significantly increases the long-term risk of arterial re-narrowing or blood clot formation. To optimize stent expansion, appropriate preparation of the diseased vessel section before stent insertion is a critical phase.\n\nThis study is a prospective, multi-center randomized trial designed to test the hypothesis that treating calcified coronary lesions with the Naviscore scoring balloon will achieve a better stent expansion and a larger final minimal stent area compared to standard lesion preparation using regular non-compliant balloons. Eligible participants will be randomized in a one-to-one ratio to one of these two lesion preparation strategies. For all included patients, standard drug-eluting stents will be deployed. The study will use intravascular ultrasound imaging to evaluate the final minimum area of the stent directly inside the treated artery at the site of the highest initial calcium burden. Participant health and clinical outcomes will be monitored for up to twelve months following the procedure.",[27,28],"Coronary Arterial Disease (CAD)","Calcific Coronary Arteriosclerosis",[30,31,32,33,34,35],"Percutaneous Coronary Intervention","Lesion Preparation","Scoring Balloon","Intravascular Ultrasound","Stent Expansion","Coronary Artery Calcification","NOT_YET_RECRUITING","2026-06-10",{"date":39,"type":40},"2026-06-16","ACTUAL",{"date":42,"type":21},"2026-07",{"date":44,"type":21},"2028-06",{"name":46,"class":47},"University of Mons","OTHER",14,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},"100639534","phase-4-comparative-effectiveness-of-alginate-magaldrate-sucralfate-proton-pump-inhibitors-and-diet-in-laryngopharyngeal-reflux-disease-100639534","NCT07611162","Comparative Effectiveness of Alginate, Magaldrate, Sucralfate, Proton Pump Inhibitors, and Diet in Laryngopharyngeal Reflux Disease","Inclusion Criteria:\n\n* Positive 24-h HEMII-pH \\> 1 event\n\nExclusion Criteria:\n\n* Smoker (\\>5 cigarettes\u002Fday) , alcohol dependence (\\>3 units\u002Fday),\n* upper respiratory tract infection within the last month,\n* pregnancy,\n* neurological or psychiatric illness,\n* previous history of neck surgery or trauma,\n* malignancy,\n* history of head and neck radiotherapy\n* active seasonal allergies or asthma.",{"count":56,"type":21},800,[58],"PHASE4","The goal of this randomized controlled trial is to compare the effectiveness of different treatments for laryngopharyngeal reflux disease (LPRD) in adult patients with confirmed symptoms and signs of the condition. The main question it aims to answer is:\n\nWhich treatment (Proton Pump Inhibitors (PPIs), alginate, magaldrate, sucralfate, or diet) leads to the greatest improvement in LPRD symptoms and clinical signs over 3 months? Researchers will compare proton pump inhibitors to alternative medical treatments and dietary management to see which approach is most effective and better tolerated.\n\nParticipants will:\n\n* undergo a clinical ENT examination with scoring of reflux signs (RSA)\n* complete symptom questionnaires (RSS) assessing severity, frequency, and impact of symptoms\n* receive one of the study treatments (medication or dietary intervention)\n* be evaluated at baseline and again after 3 months of treatment",[61],"Laryngopharyngeal Reflux Disease","2026-05-20",{"date":64,"type":40},"2026-05-28",{"date":66,"type":21},"2026-05-01",{"date":68,"type":21},"2030-05-01",{"name":46,"class":47},1,""]